Carsgen appoints dr. sylvie peltier as senior vice president of global regulatory affairs

Shanghai , oct. 31, 2022 /prnewswire/ -- carsgen therapeutics holdings limited (stock code: 2171.hk), a company focused on innovative car t-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that dr. sylvie peltier ("dr. peltier") has been appointed as senior vice president of global regulatory affairs of the company with effect from october 31 st, 2022. she will be responsible for developing global regulatory strategies, leading and driving the company's regulatory affairs activities, and initiatives in support of ind/cta/bla filing and approval of developmental products globally.
TEVA Ratings Summary
TEVA Quant Ranking